索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 引用因子
  • 宇宙IF
  • 西马戈
  • 乌尔里希的期刊目录
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • 期刊摘要索引目录
  • OCLC-WorldCat
  • 普罗奎斯特传票
  • 学者指导
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

The role of PI-3 kinase in cancer biology and approaches to the therapeutics of cancer

A Babu Vimalanathan, A Kanikkai Raja, Manoj G Tyagi*

Many types of immune cellular stimulation or toxic insults activate the generalized systemic PI3K/AKT pathway and it regulates the basic cellular functions such as transcription, proliferation, growth and survival. The modified and disturbed activation of these pathway result in development of major disease such as cancer, diabetes mellitus and autoimmune disorders. Especially, PI3K/AKT mediated signal transduction molecules and effects on gene expression that contribute to tumorigenesis. Current evidence has suggested that the PI3K/AKT pathway is visible target for novel antitherapeutic drugs. Importantly, the main objectives of the signal transduction based research are to develop effective, low cost chemotherapeutic drugs that target very dangerous cancerous cells without affecting the normal cells. Small interfering RNA (siRNA) is one of the very effective therapeutic models in cancerous gene to inhibit or mimic the PI3K/AKT pathway for anticancer treatment. Many biological, active chemotherapeutic drugs have developed to inhibit the PI3K/AKT signaling pathways. This review will focus on the PI3K/AKT pathways, its alteration in cancer progression and different chemotherapeutic drugs have been used to inhibit the different types of cancer.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证